February 8, 2019
Jacob Tolstrup elected new Chairman of the Board of Directors of Pharmacosmos
At the extraordinary general meeting of Pharmacosmos A/S on 8 February 2019, Jacob Tolstrup was elected to the Board of Directors. At the same time, the Chairman of the Board of Directors Axel Kierkegaard stepped down from the Board of Directors. At the board meeting held immediately after the extraordinary general meeting, Jacob Tolstrup was elected Chairman of the Board.
Axel Kierkegaard was elected Chairman of the Board of Pharmacosmos in April 2002. During his tenure Pharmacosmos has seen incredible growth with sales increasing more than five-fold.
Lars Christensen, President & CEO commented: "Working together with Axel Kierkegaard and having him as an advisor has been a privilege for Pharmacosmos and for me personally. I would like to express my deepest gratitude for his effort and commitment over the years".
Jacob Tolstrup brings substantial pharmaceutical commercial expertise to Pharmacosmos with more than 20 years of experience in the pharmaceutical industry including approximately four years in the US. Jacob Tolstrup is Executive Vice President, Commercial Operations at H. Lundbeck A/S, and holds a Master of Science in Business Administration & Commercial Law from Aalborg University, Denmark and an MBA from European Business College, Munich, Germany.
Tobias S. Christensen, Vice President, Corporate Development & Strategy said: "Jacob Tolstrup joining Pharmacosmos as our new Chairman of the Board is a big advantage for us as we continue our work to improve the treatment of iron deficiency We are looking forward to working with Jacob and will value his great experience as we continue to grow, not least as we work towards entering the US market with our human products"
Jacob Tolstrup, new Chairman of the Board commented: "Pharmacosmos is a very focused specialty pharma company with a strong potential for growth. I see the family-held ownership, the company culture and the inherent expertise as an excellent platform for future development of Pharmacosmos and I am looking forward to be a part of this".
Tobias S. Christensen
Vice President, Corporate Development & Strategy
Tel: +45 5948 5959
Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.
Pharmacosmos has subsidiaries in US, China, UK, Ireland, Germany, Sweden and Norway and its products are marketed in more than 80 countries around the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.
